Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia

Leukemia Research

Volumn 30, Issue 8, 2006, Pages 1043-1047

  Daskalakis, M ^a   Mauritzson, N ^b   Johansson, B ^b   Bouabdallah, K ^c   Onida, F ^d,e   Kunzmann, R ^a   Muller Berndorff H ^a   Schmitt Graff A ^a   Lubbert M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Division of Hematology   (France)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Decitabine; Karyotype; Myelodysplastic myeloproliferative overlap syndrome; Ringed sideroblasts

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CELL COUNT; CHROMOSOME 19; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE LOCATION; HUMAN; KARYOTYPE; LEUKOCYTOSIS; MALE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; SIDEROBLASTIC ANEMIA; SPLENOMEGALY; TIME SERIES ANALYSIS; TRISOMY; TRISOMY 19;

AGED; AZACITIDINE; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 19; CYTARABINE; CYTOGENETIC ANALYSIS; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FATAL OUTCOME; FEMALE; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; STEROIDS; TREATMENT OUTCOME;

EID: 33744827412     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.01.003     Document Type: Article

References (17)

1. Fenaux P., Morel P., and Lai J.L. Cytogenetics of myelodysplastic syndromes. Semin Hematol 33 (1996) 127-138
2. Hasle H., Arico M., Basso G., Biondi A., Cantu Rajnoldi A., Creutzig U., et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. EWOG-MDS. Leukemia 13 (1999) 376-385
3. Nimer S.D., and Golde D.W. The 5q-abnormality. Blood 70 (1987) 1705-1712
4. Lai L.J., Preudhomme C., Zandecki M., Flactif M., Vanrumbeke M., Lepelley P., et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 9 (1995) 370-381
5. Johansson B., Billström R., Mauritzson N., and Mitelman F. Trisomy 19 as the sole anomaly in hematologic neoplasms. Cancer Genet Cytogenet 74 (1994) 62-65
6. Mitelman F, Johansson B, Mertens F, editors. Mitelman database of chromosome aberrations in cancer; 2005. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
7. Wijermans P., Lübbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low-dose 5-aza-2′-deoxycytidine, a hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18 (2000) 956-962
8. Fenaux P., Jouet J.P., Zandecki M., Lai J.L., Simon M., Pollet J.P., et al. Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol 65 (1987) 101-106
9. Groupe Francais de Cytogenetique Hematologique. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet Cytogenet 55 (1991) 57-65
10. Onida F., Kantarjian H.M., Smith T.L., Ball G., Keating M.J., Estey E.H., et al. Prognostic factors and scoring system in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99 (2002) 840-849
11. Müller-Berndorff H, Haas PS, Kunzmann R, Schulte-Mönting, Lübbert M. Comparison of five prognostic scoring systems, the FAB and WHO classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol, in press.
12. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
13. Yen R.W., Vertino P.M., Nelkin B.D., Yu J.J., el-Deiry W., Cumaraswamy A., et al. Isolation and characterization of cDNA encoding human DNA methyltransferase. Nucleic Acids Res 20 9 (1992) 2287-2291
14. Langer F., Dingemann J., Kreipe H., and Lehmann U. Upregulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res 29 3 (2005) 325-329
15. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Köhler G., Wijermans P., et al. Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (Decitabine) treatment. Blood 100 8 (2002) 2957-2964
16. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (Decitabine) in hematopoietic malignancies. Blood 103 5 (2004) 1635-1640
17. Gore S.D., Baylin S.B., Dauses T., Grever M.R., Jiemjit A., Manning J., et al. Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacytidine and sodium phenylbutyrate. Blood 104 Suppl. (2004) 469a